Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

The aim of the study was to evaluate the efficacy and safety of 1-h infusion of recombinant human atrial natriuretic peptide (rhANP) in combination with standard therapy in patients with acute decompensated heart failure (ADHF). This was a phase III, randomized, double-blind, placebo-controlled, mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guogan, Wang, Pengbo, Li, Yishi, Liu, Wenxian, Bai, Shugong, Zhen, Yang, Li, Dongye, Yang, Ping, Chen, Yu, Hong, Lang, Sun, Jianhui, Chen, Junzhu, Wang, Xian, Zhu, Jihong, Hu, Dayi, Li, Huimin, Wu, Tongguo, Huang, Jie, Tan, Huiqiong, Zhang, Jian, Liao, Zhongkai, Yu, Litian, Mao, Yi, Ye, Shaodong, Feng, Lei, Hua, Yihong, Ni, Xinhai, Zhang, Yuhui, Wang, Yang, Li, Wei, Luan, Xiaojun, Sun, Xiaolu, Wang, Sijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
3700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782891/
https://www.ncbi.nlm.nih.gov/pubmed/26945407
http://dx.doi.org/10.1097/MD.0000000000002947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782891/
https://www.ncbi.nlm.nih.gov/pubmed/26945407
http://dx.doi.org/10.1097/MD.0000000000002947

Ejemplares similares